Catatonia Due to Lithium Neurotoxicity: A Case Report.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Lityum Nörotoksisitesine İkincil Gelişen Katatoni Vakası: Bir Olgu Sunumu.
    • Source:
      Publisher: Türkiye Sinir ve Ruh Sağliği Derneği Country of Publication: Turkey NLM ID: 9425936 Publication Model: Print Cited Medium: Internet ISSN: 2651-3463 (Electronic) Linking ISSN: 13002163 NLM ISO Abbreviation: Turk Psikiyatri Derg Subsets: MEDLINE
    • Publication Information:
      Original Publication: Ankara : Türkiye Sinir ve Ruh Sağliği Derneği
    • Subject Terms:
      Bipolar Disorder*/drug therapy ; Catatonia*/chemically induced; Humans ; Antimanic Agents/adverse effects ; Diagnosis, Differential ; Neurotoxicity Syndromes/etiology ; Neurotoxicity Syndromes/diagnosis
    • Abstract:
      Lithium may cause toxicity as it has a narrow therapeutic range. Lithium intoxication may manifest in the form of acute, acute on chronic and chronic intoxication. Neurotoxicity is a common component of chronic lithium intoxication and the symptoms include tremor, ataxia, dysarthria, extrapyramidal symptoms, hyperreflexia, seizures and status epilepticus. Although rare, catatonia could as a manifestation of lithium neurotoxicity. In this report, we present a patient with bipolar disorder presenting with catatonic symptoms secondary to lithium intoxication. We will discuss the risk factors, differential diagnosis and the treatment of catatonic symptoms. Lithium neurotoxicity may present with various clinical symptoms including catatonia, and differential diagnosis should be made well in such cases. If lithium neurotoxicity is suspected, rapid and appropriate intervention is required to prevent permanent neurological damage. Keywords: Lithium, Neurotoxicity, Catatonia.
    • References:
      J Neurosci Nurs. 2007 Jun;39(3):132-4, 192. (PMID: 17591408)
      Turk Psikiyatri Derg. 2022 Winter;33(4):255-262. (PMID: 36592104)
      Aust N Z J Psychiatry. 1996 Dec;30(6):871-3. (PMID: 9034481)
      Acta Neurol Belg. 1996 Dec;96(4):281-93. (PMID: 9008777)
      Clin Neuropharmacol. 1997 Aug;20(4):283-99. (PMID: 9260727)
      J Affect Disord. 2017 Aug 1;217:266-280. (PMID: 28437764)
      J Clin Psychopharmacol. 2007 Aug;27(4):410-2. (PMID: 17632235)
      Acta Psychiatr Scand. 2008 May;117(5):394-5; discussion 396. (PMID: 18331580)
      BMJ Case Rep. 2019 Jan 17;12(1):. (PMID: 30659009)
      J Clin Psychopharmacol. 2018 Aug;38(4):405-407. (PMID: 29912800)
      Clin J Am Soc Nephrol. 2015 May 7;10(5):875-87. (PMID: 25583292)
      Turk Psikiyatri Derg. 2023 Winter;34(4):254-261. (PMID: 38173326)
      Clin Neuropharmacol. 2005 Jan-Feb;28(1):38-49. (PMID: 15714160)
      J Psychiatr Pract. 2009 Jan;15(1):60-3. (PMID: 19182567)
      Am J Psychiatry. 1979 Jul;136(7):963-6. (PMID: 110153)
      Dement Neuropsychol. 2019 Apr-Jun;13(2):133-143. (PMID: 31285787)
      J Intensive Care Med. 2017 May;32(4):249-263. (PMID: 27516079)
      Asian J Psychiatr. 2020 Aug;52:102002. (PMID: 32506001)
      Curr Psychiatry Rep. 2011 Dec;13(6):488-92. (PMID: 21847537)
    • Accession Number:
      0 (Antimanic Agents)
    • Publication Date:
      Date Created: 20240606 Date Completed: 20240606 Latest Revision: 20240612
    • Publication Date:
      20240612
    • Accession Number:
      PMC11164078
    • Accession Number:
      10.5080/u27074
    • Accession Number:
      38842156